InvestorsHub Logo
Followers 58
Posts 10122
Boards Moderated 1
Alias Born 09/21/2016

Re: RedShoulder post# 396277

Friday, 01/06/2023 12:16:05 PM

Friday, January 06, 2023 12:16:05 PM

Post# of 461244
AVXL gets positive mention in the middle of the smoke...

Caring for patients with Alzheimer’s and other diseases costs the country over $320 billion in 2022 alone. Due to an aging population, these figures are projected to reach $1 trillion by 2050 – unless scientists discover a game-changing treatment.

The Michael J. Fox Foundation for Parkinson’s Research has been one of the leading supporters of research in the field for years. Among other projects, the foundation supports small, innovative biopharmaceutical companies researching potential treatments for Parkinson’s Disease Dementia (PDD) and related conditions.

One of the foundation’s recent research grants was awarded to New York-based Anavex Life Sciences, a company whose scientists are working on a drug to treat PDD, Rett syndrome, and other forms of dementia as well as rare diseases that impact the central nervous system. Known as ANAVEX®2-73, the drug binds to the sigma-1 receptor in a patient’s brain and spinal cord and stimulates it.

Research has shown that dementia patients have fewer of these receptors than their healthy counterparts. By stimulating the activity levels of existing sigma-1 receptors, ANAVEX®2-73 looks set to protect the health and function of nerve cells, thus reducing the symptoms of various forms of dementia. The foundation’s grant fully funded preclinical work and the drug candidate has since successfully moved on to advanced clinical trials.

From the beginning, Anavex’s approach to its research and trial phase had digital technology at its heart. The goal was to streamline the research process and shorten the time between laboratory and patient without compromising research integrity and quality.


Caring for patients with Alzheimer’s and other diseases costs the country over $320 billion in 2022 alone. Due to an aging population, these figures are projected to reach $1 trillion by 2050 – unless scientists discover a game-changing treatment.

The Michael J. Fox Foundation for Parkinson’s Research has been one of the leading supporters of research in the field for years. Among other projects, the foundation supports small, innovative biopharmaceutical companies researching potential treatments for Parkinson’s Disease Dementia (PDD) and related conditions.

One of the foundation’s recent research grants was awarded to New York-based Anavex Life Sciences, a company whose scientists are working on a drug to treat PDD, Rett syndrome, and other forms of dementia as well as rare diseases that impact the central nervous system. Known as ANAVEX®2-73, the drug binds to the sigma-1 receptor in a patient’s brain and spinal cord and stimulates it.

Research has shown that dementia patients have fewer of these receptors than their healthy counterparts. By stimulating the activity levels of existing sigma-1 receptors, ANAVEX®2-73 looks set to protect the health and function of nerve cells, thus reducing the symptoms of various forms of dementia. The foundation’s grant fully funded preclinical work and the drug candidate has since successfully moved on to advanced clinical trials.

From the beginning, Anavex’s approach to its research and trial phase had digital technology at its heart. The goal was to streamline the research process and shorten the time between laboratory and patient without compromising research integrity and quality.

https://www.europeanbusinessreview.com/digital-innovation-could-transform-rare-disease-treatment-but-short-attacks-are-putting-companies-and-patients-at-risk/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News